Amicus Therapeutics Inc

Amicus Therapeutics — Q2 2024 Earnings Presentation

23 slides from Amicus Therapeutics's earnings presentation, Aug 8, 2024

  1. Slide 1: 2Q24 Results Conference Call & Webcast

    AT T H E F O R E F RO N T O F THERAPIES FOR RARE DISEASES 2Q24 Results Conference Call & Webcast August 8, 2024

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c

  3. Slide 3: A Rare Company

    A Rare Company A leading biotech company projected to deliver 2024 total revenue growth of 26%-31%1 LEVERAGEABLE GLOBAL 2 World-Class Clinical $62M-$67M COMMERCIAL APPROVED Development FY 2024 ORGANIZATION THERAPIES Capabilities Pombiliti + Opfolda Revenue1 ~500 EMPLOYEES in 20+ Countries 14-18% Gui

  4. Slide 4: 2024 Strategic Priorities

    2024 Strategic 1 ® Galafold revenue growth of 11-16% at CER1, now raised to 14-18% Priorities A Transformative 2 ® Execute multiple successful launches of Pombiliti + Opfolda ® Year Ahead for Amicus Advance ongoing studies to support medical and scientific 3 leadership in Fabry and Pompe diseases 4

  5. Slide 5: Galafold (migalastat) Continued Growth

    Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5

  6. Slide 6: 2024 Galafold Success (as of June 30, 2024)

    2024 Galafold Success (as of June 30, 2024) Galafold is the only approved oral treatment option in Fabry disease A unique mechanism of action for Fabry patients with amenable variants $110.8M 2Q24 Galafold Revenue >60% 14-18% Share of Treated 2024 Galafold Amenable Patients Growth at CER1 2,400+ 35-

  7. Slide 7: Galafold Performance

    Galafold Performance Q2 2024 Galafold reported revenue of $110.8M (+19% growth at CER) $442M-$458M1 $388M $329M Q4 $306M $107M  Global mix of switch (~42%) and previously $261M untreated patients (~58%)2 Q3 $101M $182M  Expect non-linear quarterly growth to continue Q2 Q2 $111M due to uneven order

  8. Slide 8: Key Growth Drivers for 2024

    Key Growth Drivers for 2024 Highest patient demand in last four years lays strong foundation for continued double-digit Galafold growth in 2024  Expanding market through uptake in naïve population as well as geographic and label expansion  Increasing patient identification through ongoing medical

  9. Slide 9: Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat)

    Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 9

  10. Slide 10: Pombiliti + Opfolda Performance

    Pombiliti + Opfolda Performance Q2 2024 revenue of $15.9M, up +44% from Q1, provides strong foundation for H2 2024 $62M-67M1 Q2 $16M $11M Q1 $11M FY23 FY24 Guiding to $62M to $67M in FY 2024 Pombiliti + Opfolda Revenue at CER 10 1At CER: Constant Exchange Rates

  11. Slide 11: Successful Global Launch of Pombiliti + Opfolda Underway

    Successful Global Launch of Pombiliti + Opfolda Underway Focus in 2024 is on maximizing the number of patients on therapy by year end Patient Demand KOL Outreach Access and As of end of July 2024 Reimbursement 186 patients have been Increasing depth and breadth of Positive interactions treated or sc

  12. Slide 12: Regulatory and Clinical Updates

    Regulatory and Clinical Updates Continuing to build the body of evidence and expand commercial access  Switzerland’s Swissmedic approved Pombiliti + Opfolda on July 4, 2024  >10 reimbursement dossiers and multiple regulatory submissions throughout 2024  Ongoing clinical studies in children with l

  13. Slide 13: Corporate Outlook

    Corporate Outlook Delivering on our mission for patients and shareholders 13

  14. Slide 14: Q2 2024 Select Financial Results

    Q2 2024 Select Financial Results Q2 2024 revenue of $126.7M, up 34% and net loss reduced Q2’24 H1’24 (in thousands, except per share data) Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 GAAP net product sales $ 126,669 $ 94,503 $ 237,072 $ 180,773 GAAP cost of goods sold 11,261 9,114 24,828

  15. Slide 15: Updated Full-Year 2024 Guidance

    Updated Full-Year 2024 Guidance Previous Updated Guidance Guidance Total Revenue Growth1 26% to 31% 25% to 30% Galafold Revenue Growth1 14% to 18% 13% to 17% Pombiliti + Opfolda Revenue1 $62M to $67M $62M to $67M Non-GAAP Operating Expense $345M to $360M $345M to $365M Guiding to full-year 2024 non-

  16. Slide 16: Positioned for Significant Value Creation in 2024

    Positioned for Significant Value Creation in 2024 Unlocking the value of two unique commercial therapies in sizeable and growing markets Delivering Clear line of Accelerating sight to full-year total revenue generating non-GAAP1 growth positive profitability cashflow 16 1 Non-GAAP Net (Loss) Income

  17. Slide 17: Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases

    Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases >350 Patients* >2,600 Patients* Many Thousands of Patients* YE17 YE23 2024+ 17 *Clinical and commercial, all figures approximate

  18. Slide 18: Appendix

    Amicus Therapeutics Appendix

  19. Slide 19: Reconciliation of Non-GAAP Financial Measures

    | Append ix | Reconciliation of Non-GAAP Financial Measures Total operating expenses - as reported GAAP Research and development: Stock-based compensation Selling, general and administrative: Stock-based compensation Loss on impairment of assets Changes in fair value of contingent consideration paya

  20. Slide 20: Reconciliation of Non-GAAP Financial Measures

    | Appendix II Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands, except share and per share amounts) GAAP net loss Share-based compensation Changes in fair value of contingent consideration payable Depreciation and amortization Loss on impairment of assets Restruc

  21. Slide 21: Environmental, Social, & Governance (ESG) Snapshot

    Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to drive Diversity, Equity, & Management sustainability with our partners by Inclusion (DEI) Address a rare genetic disease Committed to producing incorporating Programs we Pledge to support a more inclusive

  22. Slide 22: FX Sensitivity and Galafold Distribution of Quarterly Sales

    FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q2 2024: Currency Variances: Q2 2023 Q2 2024 YoY Variance USD/ EUR 1.089 1.076 (1.1%) Distribution of Galafold Revenue GBP 1.251 1.262 0.8% by Quarter over Past 5 Years: JPY 0.007 0.006 (11.9%) Q1 Q2 Q3 Q4 5 Yea

  23. Slide 23: Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises

    Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises INDICATION D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L FAB RY F RANC H IS E Galafold® (migalastat) Fabry Genetic Medicines Next-Generation Chaper

Amicus Therapeutics — Q2 2024 Earnings Presentation on 6ix